• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neurosurgery >Intravenous low-dose native tissue plasminogen activator for distal embolism in the middle cerebral artery divisions or branches: a pilot study.
【24h】

Intravenous low-dose native tissue plasminogen activator for distal embolism in the middle cerebral artery divisions or branches: a pilot study.

机译：静脉低剂量天然组织纤溶酶原激活剂用于大脑中动脉分支或分支远端栓塞：一项初步研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: We prospectively evaluated the safety and efficacy of an intravenous infusion of low-dose native tissue plasminogen activator for distal embolisms in the middle cerebral artery divisions or branches. METHODS: Twenty patients were selected according to the following computed tomographic and angiographic criteria and treated with intravenous infusion of 7.2 mg of tisokinase: 1) no early ischemic changes on the initial computed tomographic scan, and 2) embolic occlusion of the middle cerebral artery divisions or branches without the involvement of the lenticulostriate arteries. For comparison, the records of 12 patients from previous years who met the above inclusion criteria but underwent no thrombolytic therapy were reviewed retrospectively. The degree of neurological recovery was assessed using the National Institutes of Health Stroke Scale at 24 hours after admission. Major neurological improvement was defined as a decrease in the stroke score by 4 points or more. RESULTS: There was no significant difference in stroke scores at the time of admission between the treatment group (mean +/- standard deviation, 12.8 +/- 2.8) and the untreated group (14.0 +/- 2.4). In the treatment group, major neurological improvement was seen in 17 (85%) of 20 patients, whereas in the untreated group only 5 (41.7%) of 12 patients showed major neurological improvement (P < 0.05). The mean score at 24 hours in the treatment group (3.6 +/- 3.5) was significantly lower than that in the untreated group (9.4 +/- 7.3) (P < 0.05). There was no hemorrhagic complication with neurological exacerbation in the treatment group. CONCLUSION: Even with delayed initiation (>3 h after symptom onset), intravenous infusion of low-dose tisokinase may be safe and effective for small distal emboli in the middle cerebral artery divisions or branches, when early ischemic changes on computed tomographic scans and involvement of the lenticulostriate arteries are absent.
机译：目的：我们前瞻性评估了静脉输注低剂量天然组织纤溶酶原激活剂对脑中动脉分支或分支远端栓塞的安全性和有效性。方法：根据以下计算机断层扫描和血管造影标准选择20例患者，并静脉输注7.2 mg的Tisokinase：1）最初的计算机断层扫描无早期缺血性改变; 2）大脑中动脉的栓塞闭塞或分支，而没有细小动脉的参与。为了比较，回顾性地回顾了前几年符合上述纳入标准但未接受溶栓治疗的12例患者的记录。入院后24小时使用美国国立卫生研究院卒中量表评估神经系统恢复程度。主要的神经功能改善定义为卒中评分降低4分或更多。结果：入院时，治疗组（平均+/-标准偏差，12.8 +/- 2.8）与未治疗组（14.0 +/- 2.4）之间的卒中得分无显着差异。在治疗组中，有20名患者中有17名（85％）出现了重大神经功能改善，而在未治疗组中，只有12名患者中有5名（41.7％）出现了重大神经功能改善（P <0.05）。治疗组24小时平均得分（3.6 +/- 3.5）显着低于未治疗组（9.4 +/- 7.3）（P <0.05）。治疗组无出血并发症并伴有神经功能恶化。结论：即使在延迟开始（症状发作后> 3 h）时，当在计算机断层扫描和早期CT检查中发现局部缺血性改变时，静脉输注低剂量tisokinase对于脑中动脉分支或分支中的小远端栓塞仍是安全有效的。缺少小脑动脉。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号